Adequacy of new systemic antifungal agents prescriptions in a teaching hospital;Revue de pertinence des prescriptions des nouveaux antifongiques systémiques dans un hôpital universitaire

Medecine et Maladies Infectieuses

Volumn 37, Issue SUPPL. 3, 2007, Pages

  Pavese, P ^a   Ouachi, Z ^b   Vittoz, J P ^b   Lebeau, B ^b   Foroni, L ^b   Allenet, B ^b   Stahl, J P ^a   Francois P ^b  

^a HÔPITAL MICHALLON   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Antifungals; Practice assessment; Systemic mycosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; VORICONAZOLE; ANTIFUNGAL AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG MISUSE; FEMALE; HUMAN; IMMUNE DEFICIENCY; INFECTION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PRACTICE GUIDELINE; PRESCRIPTION; TEACHING HOSPITAL; FRANCE; MIDDLE AGED; RETROSPECTIVE STUDY; STANDARD; STATISTICS;

ANTIFUNGAL AGENTS; FEMALE; FRANCE; GUIDELINE ADHERENCE; HOSPITALS, TEACHING; HUMANS; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES;

EID: 36849028216     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2007.05.009     Document Type: Article

References (21)

1. Eggimann P., and Pittet D. Candidoses invasives en réanimation. Schweiz. Med. Wochenschr. 130 (2000) 1525-1537
2. Morin O. Historique des antifongiques et évolution de l'épidémiologie. Journée interdisciplinaire sur les infections fongiques, ed. Infections fongiques : résistances et nouvelles modalités thérapeutiques (2003), Optimed, Paris 11-28
3. Johnson M.D., Kleinberg M., Danziger L., and Ostrosky-Zeichner L. Pharmacoeconomics of antifungal pharmacotherapy: challenges and future directions. Expert Opin. Pharmacother. 6 (2005) 2617-2632
4. Pacetti S.A., and Gelone S.P. Caspofungin acetate for treatment of invasive fungal infections. Ann. Pharmacother. 37 (2003) 90-98
5. Pearson M.M., Rogers P.D., Cleary J.D., and Chapman S.W. Voriconazole: a new triazole antifungal agent. Ann. Pharmacother. 37 (2003) 420-432
6. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al., Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38 (2004) 161-189
7. Stevens D.A., Kan V.L., Judson M.A., Morrison V.A., Dummer S., Denning D.W., et al., Infectious Diseases Society of America. Practice guidelines for diseases caused by Aspergillus. Clin. Infect. Dis. 30 (2000) 696-709
8. Conférence de consensus française organisée conjointement par la Sfar, la Spilf, et la SRLF. Prise en charge des candidoses et aspergilloses invasives de l'adulte. Med. Mal. Infect. (2004) 1-118 (Spécial)
9. Jones M.I., Greenfield S.M., and Bradley C.P. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ 323 (2001) 378-381
10. Gauzit R., Cohen Y., Dupont H., Hennequin C., Montravers P., Timsit J.F., et al. Infections à Candida spp en réanimation. Enquête sur les pratiques françaises. Presse Med. 32 (2003) 440-449
11. Agence nationale d'accréditation et évaluation en santé. Le bon usage des antibiotiques à l'hôpital : recommandations pour maîtriser le développement de la résistance bactérienne. Anaes; Paris 1996. http://www.anaes.fr.
12. Dannaoui E., Lortholary O., and Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob. Agents Chemother. 48 (2004) 970-978
13. Meletiadis J., Petraitis V., Petraitiene R., Lin P., Stergiopolou T., Kelaher A.M., et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J. Infect. Dis. 194 (2006) 1008-1018
14. Petraitis V., Petraitiene R., Sarafandi A.A., Kelaher A.M., Lyman C.A., Casler H.E., et al. Combination therapy in treatment of experimental aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. 187 (2003) 1831-1833
15. Kirkpatrick W.R., Perea S., Coco B.J., and Patterson T.F. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46 (2002) 2564-2568
16. Johnson M.D., MacDougall C., Ostrosky-Zeichner L., Perfect J.R., and Rex J.H. Combination antifungal therapy. Antimicrob. Agents Chemother. 48 (2004) 693-715
17. Kontoyannis D.P., Hachem R., Lewis R.E., Rivero G.A., Torres H.A., Thornby J., et al. Efficacity and toxicity of caspofungin in combination with liposomal amphotericin B as primary salvage treatment of invasive aspergillosis in patients with haematologic malignancies. Cancer 98 (2003) 392-399
18. Marr K.A., Boeck M., Carter R.A., Kim H.W., and Corey L. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39 (2004) 797-802
19. Singh N., Limaye A.P., Forrest G., Safdar N., Munoz P., Pursell K., et al. Combinaison of voriconazole and caspofungine as primary therapy for invasive aspergillosis in solid organ transplant recipients. Transplantation 81 (2006) 320-326
20. Viscoli C. Combination therapy for invasive aspergillosis. Clin. Infect. Dis. 39 (2004) 803-805
21. Denig P., Haaijer-Ruskamp F.M., and Zijsling D.H. How physicians choose drugs. Soc. Sci. Med. 27 (1988) 1381-1386